Dharmacon has recently introduced the miRidian microRNA inhibitors and mimics.
According to the company, the inhibitors and mimics are based on known or predicted miRNA sequences for human, mouse and rat as defined in the Wellcome Trust Sanger Institute's miRBase.
MiRNA inhibitors facilitate loss-of-function studies, while miRNA mimics may be useful for gain-of function studies, Dharmacon said.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
